LIMITED STOCK AVAILABLEPRICES SHOWN WHERE AVAILABLE
PNC 27

CELLULAR / SINGLE

PNC 27

10MG
Important medical and research notice

This content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.

Research Overview

A 32-amino-acid peptide containing an HDM-2-binding domain linked to a membrane-penetrating sequence, studied in preclinical cancer-cell research.

Available Strengths

  • 10MG (PN10)

Research Protocol

Reference gradual titration

PeriodDoseU-100 unitsVolume
Weeks 1–20.1 mg10.01 mL
Weeks 3–40.2 mg20.02 mL
Weeks 5–80.3 mg30.03 mL
Weeks 9–120.4 mg40.04 mL
Weeks 13–160.5 mg50.05 mL

Reconstitution

Water volume1 mLConcentration10 mg/mLAdministrationSubcutaneousFrequencyOnce dailyCycle length8–12 weeks in the reference protocol, optionally extended to 16 weeks.

≈10.0 mg/mL once reconstituted

  1. Draw 1.0 mL of bacteriostatic water per 10 mg vial.
  2. Inject slowly along the vial wall; swirl gently until dissolved.

Research context

Preclinical research indicates selective binding to HDM-2 on cancer-cell membranes, inducing membrane destabilization; the cited source stresses that no human clinical trials exist and that regulators have not established safety data.

Storage

−20°C minimum; −80°C preferred. 2–8°C, use within ~30 days; avoid freeze–thaw cycles.

Research Notes

  • For educational and research reference only. Not medical advice and not intended for unsupervised human use.
  • DXBTides' 10 mg vial has no dedicated source page; the source's own 30 mg vial page was used, holding its 10.0 mg/mL concentration constant and scaling reconstitution water down to 1.0 mL for this smaller vial — the daily mcg dose and resulting injection volumes are unchanged from the source's own figures.
  • The cited source explicitly states no human clinical trials exist for PNC-27 and that regulators consider it unapproved with no established safety data.

References

Cited FDA regulatory guidance on unapproved research compounds↗

Source reference: PeptideDosages.com · 2026-08-18 · Mathematically derived for this strength from the compound's verified reference data

View in catalogueAll research protocols